Edward Joseph Lesnefsky

Dr. Edward Joseph Lesnefsky

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2011 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
LGLudovic Gomez
Ludovic Gomez
MPMelanie Paillard
Melanie Paillard
MPMegan Price
Megan Price
QCQun Chen
Qun Chen
GTGeoffrey Teixeira
Geoffrey Teixeira
ELEdward Joseph Lesnefsky
Edward Joseph Lesnefsky

1 September 2012 in Translational Research
Verified
Journal Article
Closed access
CTChristine Tanaka-Esposito
Christine Tanaka-Esposito
QCQun Chen
Qun Chen
ELEdward Joseph Lesnefsky
Edward Joseph Lesnefsky

1 August 2014 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
HAHema S. Aluri
Hema S. Aluri
DSDavid C. Simpson
David C. Simpson
JAJeremy C. Allegood
Jeremy C. Allegood
YHYing Hu
Ying Hu
KSKarol Szczepanek
Karol Szczepanek
ELEdward Joseph Lesnefsky
Edward Joseph Lesnefsky

1 January 2012 in Journal of Aging Research
Verified
Journal Article
Open access
PDF file
QCQun Chen
Qun Chen
TRThomas Ross
Thomas Ross
YHYing Hu
Ying Hu
ELEdward Joseph Lesnefsky
Edward Joseph Lesnefsky
Myocardial injury is increased in the aged heart following ischemia-reperfusion (ISC-REP) compared to adult hearts. Intervention at REP with ischemic postconditioning decreases injury in the adult heart by attenuating mitochondrial driven cell injury. Unfortunately, postconditioning is ineffective in aged hearts. Blockade of electron transport at the onset of REP with the reversible inhibitor amobarbital (AMO) decreases injury in adult hearts. We tested if AMO treatment at REP protects the aged heart via preservation of mitochondrial integrity. Buffer-perfused elderly Fischer 344 24 mo. rat hearts underwent 25 min global ISC and 30 min REP. AMO (2.5 mM) or vehicle was given for 3 min at the onset of REP. Subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria were isolated after REP. Oxidative phosphorylation (OXPHOS) and mitochondrial inner membrane potential were measured. AMO treatment at REP decreased cardiac injury. Compared to untreated ISC-REP, AMO improved inner membrane potential in SSM and IFM during REP, indicating preserved inner membrane integrity. Thus, direct pharmacologic modulation of electron transport at REP protects mitochondria and decreases cardiac injury in the aged heart, even when signaling-induced pathways of postconditioning that are upstream of mitochondria are ineffective.

25 March 2016 in Molecules
Verified
Journal Article
Open access
PDF file
JSJohn M. Saathoff
John M. Saathoff
KLKai Liu
Kai Liu
JCJeremy E. Chojnacki
Jeremy E. Chojnacki
LHLiu He
Liu He
Qun ChenQun Chen
Qun Chen
SZShijun Zhang
Shijun Zhang
We have recently developed a bivalent strategy to provide novel compounds that potentially target multiple risk factors involved in the development of Alzheimer’s disease (AD). Our previous studies employing a bivalent compound with a shorter spacer (17MN) implicated that this compound can localize into mitochondria and endoplasmic reticulum (ER), thus interfering with the change of mitochondria membrane potential (MMP) and Ca2+ levels in MC65 cells upon removal of tetracycline (TC). In this report, we examined the effects by a bivalent compound with a longer spacer (21MO) in MC65 cells. Our results demonstrated that 21MO suppressed the change of MMP, possibly via interaction with the mitochondrial complex I in MC65 cells. Interestingly, 21MO did not show any effects on the Ca2+ level upon TC removal in MC65 cells. Our previous studies suggested that the mobilization of Ca2+ in MC65 cells, upon withdraw of TC, originated from ER, so the results implicated that 21MO may preferentially interact with mitochondria in MC65 cells under the current experimental conditions. Collectively, the results suggest that bivalent compounds with varied spacer length and cell membrane anchor moiety may exhibit neuroprotective activities via different mechanisms of action.

15 October 2013 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
QCQun Chen
Qun Chen
ELEdward Joseph Lesnefsky
Edward Joseph Lesnefsky